These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities.
    Author: Gill WB, Schumacher GF, Bibbo M, Straus FH, Schoenberg HW.
    Journal: J Urol; 1979 Jul; 122(1):36-9. PubMed ID: 37351.
    Abstract:
    Epididymal cysts and/or hypoplastic testes have been found in 31.5 per cent of 308 men exposed to diethylstilbestrol in utero, compared to 7.8 per cent of 307 placebo-exposed controls. Analyses of the spermatozoa have revealed severe pathological changes (Eliasson score greater than 10) in 134 diethylstilbestrol-exposed men (18 per cent) and 87 placebo-exposed men (8 per cent). Further investigation of the 26 diethylstilbestrol-exposed men with testicular hypoplasia has revealed that 65 per cent had a history of cryptorchidism. Only 1 of the 6 placebo-exposed controls with testicular hypoplasia had a history of testicular maldescent. Although none of our Diekmann's lying-in study group has had carcinoma to date one must keep in mind the reported increased risk of testicular carcinoma in testes that are or were cryptorchid. A 25-year-old man who was not part of the study group was treated recently by us for a testicular carcinoma ( mixed anaplastic seminoma plus embryonal cell carcinoma) and he had a history of diethylstilbestrol exposure in utero and cryptorchidism. 31.5% of 308 men exposed to diethylstilbestrol (DES) in utero had epididymal cysts and/or hypoplastic testes compared with 7.8% of 307 placebo-exposed controls. Analyses of the sperm revealed severe pathological changes (Eliasson score 10) in 134 DES-exposed men (18%) and 87 placebo-exposed men (8%). 26 DES-exposed men with testicular hypoplasia were further investigated, and 65% had a history of cryptorchidism. Only 1/6 placebo-exposed controls with testicular hypoplasia had a history of testicular maldescent. Although none of the 300 men exposed to DES in this 2-decade-old double-blind prospective study has had carcinoma to date, the reported increased risk of testicular carcinoma in testes that are or were cryptorchid must be remembered. A 25-year-old man who was not part of the prospective study group was treated recently by the authors for a testicular carcinoma (a mixed anaplastic seminoma plus embryonal cell carcinoma) and he had a history of DES exposure in utero and cryptorchidism.
    [Abstract] [Full Text] [Related] [New Search]